ArticleIntegrative medicine research2026
Efficacy and safety of modified Gwakjeongtang (herbal medicine) for diarrhea-predominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial.
Article in Integrative medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Irritable bowel syndrome (IBS) significantly impairs quality of life, and current treatments often provide insufficient symptom relief. Gwakjeongtang is the most frequently prescribed herbal medicine for IBS patients in Korea. We aimed to explore the efficacy and safety of modified Gwakjeongtang (mGJT) compared with placebo in patients with diarrhea-predominant IBS (IBS-D). Methods: This pilot double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted at a single academic medical center from September 2023 to January 2025. Adults with IBS-D meeting Rome IV criteria were enrolled. Of 63 participants screened, 60 were randomized 1:1 to receive mGJT granules (10 g) or placebo administered orally three times daily for 4 weeks. The primary outcome was overall response rate, defined as achieving daily response criteria (≥30% reduction in worst daily abdominal pain intensity from baseline and Bristol Stool Scale ≤5 for all bowel movements) on ≥50% of treatment days over 4 weeks. Results: Among 60 randomized participants (16 male; mean age 46.0 years), 59 (98.3%) completed primary outcome assessment. The overall response rate was significantly higher with mGJT than placebo (55.2% vs. 26.7%; odds ratio 3.4; 95% confidence interval 1.1-10.1; P=.03). Sensitivity analysis assuming the missing participant was a nonresponder showed consistent results (53.3% vs. 26.7%; odds ratio 3.1; 95% confidence interval 1.1-9.3; P=.04). No intervention-related adverse events occurred. Conclusion: These pilot findings suggest mGJT may benefit patients with IBS-D. Confirmation in a larger definitive trial is warranted given the pilot study limitations and small sample size. Trial registration: Clinical Research Information Service of Korea (KCT0008523).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.